Crinetics Pharmaceuticals focuses on rare endocrine diseases and tumors. Shares were sold at $43.86 each, totaling $131,580, amid a $3.53 billion market cap. Insider Stephen Betz sold 24,000 shares in the past year, without any purchases.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing